Fluvoxamine for the treatment of COVID-19

David R. Boulware; Mahsa Abassi

doi:10.1016/S2214-109X(21)00590-8

Fluvoxamine for the treatment of COVID-19

Medicine - Infectious Disease and International Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e329
Journal	The Lancet Global Health
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/S2214-109X(21)00590-8
State	Published - Mar 2022

PubMed: MeSH publication types

Letter
Comment

Publisher link

10.1016/S2214-109X(21)00590-8

Find It

Find It at U of M Libraries

Cite this

@article{892957e7245d4675bb8eaf5725139c4c,

title = "Fluvoxamine for the treatment of COVID-19",

author = "Boulware, {David R.} and Mahsa Abassi",

year = "2022",

month = mar,

doi = "10.1016/S2214-109X(21)00590-8",

language = "English (US)",

volume = "10",

pages = "e329",

journal = "The Lancet Global Health",

issn = "2214-109X",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Fluvoxamine for the treatment of COVID-19

AU - Boulware, David R.

AU - Abassi, Mahsa

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85124541783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124541783&partnerID=8YFLogxK

U2 - 10.1016/S2214-109X(21)00590-8

DO - 10.1016/S2214-109X(21)00590-8

M3 - Letter

C2 - 35180409

AN - SCOPUS:85124541783

VL - 10

SP - e329

JO - The Lancet Global Health

JF - The Lancet Global Health

SN - 2214-109X

IS - 3

ER -

Fluvoxamine for the treatment of COVID-19

PubMed: MeSH publication types

Publisher link

Find It

Other files and links

Cite this